Industry Sessions Program
Discover the industry symposia taking place at WCN on Sunday March 29, Monday March 30 and Tuesday March 31. These sessions, delivering the latest advancements in global kidney care, are scheduled at different times throughout the days.
Select industry symposia will be livestreamed with open-access – see more in the description below. All industry symposia will be available on-demand on the ISN Academy after the congress.
Lunch will be provided to attendees of lunch symposia. Selected breakfast and afternoon symposia will provide light refreshments.
- Bringing innovative CKD treatments to patients without delay: Barriers and Solutions
- Organized by AstraZeneca
- 8:10 – 9:10 | Room 301+302 | Slot 5
- Pediatric Nephrotic Syndrome
- Organized by Chugai Pharmaceutical Co.,Ltd.
- 08:10 – 09:10 | Room 303 | Slot 2
- Comprehensive management of Chronic Kidney Disease : Insights from Japan
- Organized by Kowa Co Ltd
- 08:10 – 09:10 | Room 315 | Slot 1
- CKD-MBD
- Organized by Kyowa Kirin
- 08:10 – 09:10 | Room 503 | Slot 4
- Uric acid and kidney disease
- Organized by MOCHIDA PHARMACEUTICAL CO.,LTD.
- 08:10 – 09:10 | Room 304 | Slot 3
- Targeting pathogenic IgA in IgA Nephropathy
- The scientific content of this symposium has been independently developed by ISN. Supported by Takeda
- 08:10 – 09:10 | Room 501+502 | Slot 6
- Addressing unmet needs in immune mediated kidney diseases, one antibody at a time
- Organized by Biogen
- 12:50 – 13:50 | Room 303 | Slot 14
Hypertension Management Aimed at Achieving Target Blood Pressure: The Clinical Utility of Mineralocorticoid Receptor Antagonists- Organized by Daiichi-Sankyo
- 12:50 – 13:50 | Room 501+502 | Slot 18
- Every note matters: collective action to change the tune of IgA nephropathy
- Organized by Novartis Pharma AG
- 12:50 – 13:50 | Room 503 | Slot 16
- Exploring the Role of APRIL in IgA Nephropathy: Pathogenesis to Progression
- Organized by Otsuka
- 12:50 – 13:50 | Rooma 301+302 | Slot 17
-
WILL BE LIVE STREAMED
- Shared Decision-Making in Dialysis: Turning Conversations into Care
- Organized by Vantive
- 12:50 – 13:50 | Room 304 | Slot 15
-
WILL BE LIVE STREAMED
Hyperkalemia in CKD and Heart Failure- Organized by Zeria Pharmaceutical Co., Ltd.
- 12:50 – 13:50 | Room 315 | Slot 13
- The Complement Connection: Rethinking Disease Progression in IgA Nephropathy
- Organized by Alexion Pharmaceuticals Inc.
- 17:00 – 18:00 | Room 304 | Slot 27
-
WILL BE LIVE STREAMED
- Conquering Kidney Disease: Strategies, Evidence, and Innovations Worldwide
- Organized by AstraZeneca K.K.
- 17:00 – 18:00 | Room 501+502 | Slot 30
Evolving Landscape of IgA Nephropathy in 2026 and Beyond- Organized by Chugai Pharmaceutical Co.,Ltd.
- 17:00 – 18:00 | Room 303 | Slot 26
- Trends in global kidney care
- Organized by DaVita
- 17:00 – 18:00 | Room 315 | Slot 25
- Evaluating new treatment options for chronic kidney disease in children: the EMPA-KIDNEY KIDS trial
- Organized by Boehringer Ingelheim GmbH
- 8:10 – 9:10 | Room 304 | Slot 33
- Complement-Mediated Kidney Disease: From Mechanisms to Therapies
- Organized by eleva GmbH
- 8:10 – 9:10 | Room 315 | Slot 31
- GLP1-RAs in Kidney Disease: Mechanisms, Applications in Clinical Practice and the Future
- The scientific content of this symposium has been independently developed by ISN. Supported by Novo Nordisk
- 8:10 – 9:10 | Room 301+302 | Slot 35
-
WILL BE LIVE STREAMED
- New horizons in C3G and primary IC-MPGN: navigating the future of patient care
- Organized by Swedish Orphan Biovitrum AB
- 8:10 – 9:10 | Room 503 | Slot 34
- Emerging Therapies in IgA Nephropathy: Innovations in B-Cell Modulation and Dual BAFF/APRIL Inhibition
- Organized by Vera Therapeutics
- 8:10 – 9:10 | Room 501+502 | Slot 36
- Combination with Confidence: Finerenone for Kidney and Heart Protection
- Organized by Bayer AG
- 12:50 – 13:50 | Room 501+502 | Slot 48
- CKD in focus: Enhancing risk detection and management approaches
- Organized by Boehringer Ingelheim GmbH
- 12:50 – 13:50 | Room 304 | Slot 45
- The Evolving IgAN Treatment Paradigm- What´s New?
- Organized by Calliditas Therapeutics
- 12:50 – 13:50 | Room 303 | Slot 44
- KDIGO presents the Importance of Targeting IgAN Disease Drivers: Real-World Practice Using Case-based Illustrations
- Organized by KDIGO
- 12:50 – 13:50 | Room 301+302 | Slot 47
- A New Era for Patients with C3G: Redefining Standard of Care
- Organized by Novartis Pharma AG
- 12:50 – 13:50 | Room 503 | Slot 46
- Reimagining Anemia Management in CKD: Evolution with HIF-PHIs
- Organized by Zydus LifeSciences
- 12:50 – 13:50 | Room 315 | Slot 43
- The significance of potassium management in CKD treatment
- Organized by AstraZeneca K.K.
- 17:00 – 18:00 | Room 303 | Slot 56
- Beyond the kidneys: the importance of early intervention and managing cardiovascular risk in patients with CKD
- Organized by The Boehringer Ingelheim and Eli Lilly and Company Alliance
- 17:00 – 18:00 | Room 301+302 | Slot 59
- New Trends in Lupus Nephritis
- Organized by Otsuka
- 17:00 – 18:00 | Room 304 | Slot 57
- Comprehensive Management of Fabry Disease: Latest Evidence from Korea and Japan
- Organized by Sanofi K. K.
- 17:00 – 18:00 | Room 315 | Slot 55
- Rethinking IgA Nephropathy Through Mucosal Immunity: Integrating Tonsillar and Intestinal Perspectives
- Organized by Viatris Pharmaceuticals Japan G.K.
- 17:00 – 18:00 | Room 503 | Slot 58
- Revisiting MR-Mediated Electrolyte Imbalance at the Tissue Level: Implications for MR Blockade and JSH2025 Guidelines
- Organized by Daiichi-Sankyo
- 8:00 – 9:00 | Room 303 | Slot 61
Spotlight Stage
Located in exhibition hall the Spotlight Stages features short, dynamic and interactive presentations from industry, ISN programs, ISN social media team and more.
Sunday, March 29, 2026
- Atypical hemolytic uremic syndrome (aHUS) in focus
- Organized by Alexion Pharmaceuticals Inc.
- 11:00 – 12:00 | Spotlight Stage 1 | Slots 10+12
- From evidence to everyday practice: key aspects in the management of patients with non-diabetic CKD
- Organized by eleva GmbH
- 14:10 – 14:40 | Spotlight Stage 1 | Slot 20
Monday, March 30, 2026
- From evidence to everyday practice: key aspects in the management of patients with non-diabetic CKD
- Organized by BioKindle
- 14:10 – 14:40 | Spotlight Stage 1
Sunday, March 29, 2026
- Translating intention into action: Growing and sustaining home dialysis program
- Organized by Vantive
- 11:35 – 12:05 | Spotlight Stage 2 | Slot 9
- Treating CV risk in CKD: from identification to intervention
- Organized by The Boehringer Ingelheim and Eli Lilly and Company Alliance
- 14:30 – 15:00 | Spotlight Stage 2 | Slot 19
- Utilizing Remote Patient Management in PD Treatment: Sharesource & MyPD Enables Team-Based Care and Healthcare Collaboration
- Organized by Vantive
- 15:15 – 15:45 | Spotlight Stage 2 | Slot 21
Monday, March 30, 2026
- Guided by evidence: a unified approach to CKD, diabetes and HF management
- Organized by Bayer AG
- 15:15 – 15:45 | Spotlight Stage 2 | Slot 51